41
Participants
Start Date
November 8, 2022
Primary Completion Date
December 20, 2024
Study Completion Date
December 20, 2024
LP352, bexicaserin
LP352 6 mg, 9 mg or 12 mg administered three times daily, orally or through G-tube
Alfred Health, Melbourne
Austin Health, Heidelberg
Queensland Children's Hospital, South Brisbane
Northwell Health, New York
Northeast Regional Epilepsy Group, Staten Island
Boston Children's Health Physicians LLP, Hawthorne
Mid-Atlantic Epilepsy and Sleep Center, Bethesda
Wake Forest University School of Medicine, Winston-Salem
Northwest Florida Clinical Research Group, Gulf Breeze
Advent Health Orlando, Orlando
Research Institute of Orlando, Orlando
University of Miami, Miami
University of South Florida, Tampa
University Hospitals Cleveland Medical Center, Cleveland
Spectrum Health, Grand Rapids
Mayo Clinic, Rochester
Northwestern University Feinberg School of Medicine, Chicago
Washington University School of Medicine, St Louis
Arkansas Children's Hospital, Little Rock
Child Neurology Consultants of Austin, Austin
Austin Epilepsy Care Center, Austin
University of Utah, Salt Lake City
Rancho Los Amigos National Rehabilitation Center (RLANRC), Downey
University of California San Francisco, San Francisco
Hawaii Pacific Neuroscience, Honolulu
Providence Neurological Specialties-East, Portland
University of Washington Valley Medical Center, Renton
OnSite Clinical Solutions LLC, Charlotte
Lead Sponsor
Longboard Pharmaceuticals
INDUSTRY